These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23284637)

  • 1. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
    Betts G; Poyntz H; Stylianou E; Reyes-Sandoval A; Cottingham M; Hill A; McShane H
    PLoS One; 2012; 7(12):e50447. PubMed ID: 23284637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
    Vordermeier HM; Villarreal-Ramos B; Cockle PJ; McAulay M; Rhodes SG; Thacker T; Gilbert SC; McShane H; Hill AV; Xing Z; Hewinson RG
    Infect Immun; 2009 Aug; 77(8):3364-73. PubMed ID: 19487476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
    Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
    Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
    Kou Y; Xu Y; Zhao Z; Liu J; Wu Y; You Q; Wang L; Gao F; Cai L; Jiang C
    Immunol Lett; 2017 Oct; 190():51-57. PubMed ID: 28728855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
    Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
    J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sendai Virus Mucosal Vaccination Establishes Lung-Resident Memory CD8 T Cell Immunity and Boosts BCG-Primed Protection against TB in Mice.
    Hu Z; Wong KW; Zhao HM; Wen HL; Ji P; Ma H; Wu K; Lu SH; Li F; Li ZM; Shu T; Xu JQ; Lowrie DB; Fan XY
    Mol Ther; 2017 May; 25(5):1222-1233. PubMed ID: 28342639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.
    Lu J; Wang C; Zhou Z; Zhang Y; Cao T; Shi C; Chen Z; Chen L; Cai C; Fan X
    Clin Dev Immunol; 2011; 2011():617892. PubMed ID: 21461375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A.
    Stylianou E; Griffiths KL; Poyntz HC; Harrington-Kandt R; Dicks MD; Stockdale L; Betts G; McShane H
    Vaccine; 2015 Nov; 33(48):6800-8. PubMed ID: 26478198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model.
    Dou J; Tang Q; Yu F; Yang H; Zhao F; Xu W; Wang J; Hu W; Hu K; Liou C; Feng He X; Wang Y
    Immunobiology; 2010; 215(2):133-42. PubMed ID: 19450898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.
    Pérez de Val B; Villarreal-Ramos B; Nofrarías M; López-Soria S; Romera N; Singh M; Abad FX; Xing Z; Vordermeier HM; Domingo M
    Clin Vaccine Immunol; 2012 Sep; 19(9):1339-47. PubMed ID: 22761299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
    Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
    J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
    Santosuosso M; McCormick S; Zhang X; Zganiacz A; Xing Z
    Infect Immun; 2006 Aug; 74(8):4634-43. PubMed ID: 16861651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against
    Stylianou E; Pinpathomrat N; Sampson O; Richard A; Korompis M; McShane H
    Front Immunol; 2023; 14():1263457. PubMed ID: 37869008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.